Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42205674
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Short title:
Primary objective:
To evaluate the impact of additional adverse cytogenetic abnormalities on relapse-free survival after allo-SCT in MDS with very poor risk cytogenetics.
Key inclusion criteria:
MDS
CR1, CR2 and beyond
Age >= 18
MDS with more than 3 cytogenetic abnormalities at diagnosis
First allogeneic SCT
Allogeneic SCT from matched family or matched unrelated donor between 2000 and 2016
CR1, CR2 and beyond
Age >= 18
MDS with more than 3 cytogenetic abnormalities at diagnosis
First allogeneic SCT
Allogeneic SCT from matched family or matched unrelated donor between 2000 and 2016
Country:
Principal investigator:
Xavier Poiré
EBMT Study coordinator:
Linda Koster
Study coordinator email:
cmwpebmt@lumc.nl